The mechanism of acute nephrotoxicity following the administration of amphotericin B (AmpB) remains unclear despite a number of studies describing hypermagnesuria, hyperkaluria, and hemodynamic changes. The present experiments attempted to elucidate the mechanism by using a novel hemorheologic probe, pentoxifyiline (PTX). Acute studies were performed with rats given single intravenous doses of AmpB (1 mg/kg of body weight) with or without intraperitoneal PTX (45 mg/kg). Renal function, assessed by inulin clearance (CLIN) and electrolyte handling, and morphology were compared with those of controls given sterile water and PTX. A significant decrease in CLI not observed in rats given AmpB and PTX or in the controls was found in rats given AmpB. Electrolyte handling was not different among groups. Whereas pronounced (3 and 4+ on a scale of mild to significant [1+ to 4+]) vascular congestion was found in rats given AmpB, rats coadministered PTX had mild (1 and 2+) meduliary and glomerular vascular congestion. In chronic studies, intravenous AmpB (1 mg/kg per day) or sterile water was coadministered with intraperitoneal PTX (45 mg/kg every 12 h) or saline for 10 days. Mean CLIN of rats coadministered AmpB and PIX was not significantly different from that of PTX control rats (1.61 ± 0.19 versus 1.31 ± 0.29 ml/min per g of kidney weight). A 46% decline in CLIN was found in rats treated with AmpB and saline (P < 0.05). Renal sodium and potassium excretions were increased in both AmpB-treated groups compared with controls. Coupled with histologic evidence of the acute studies, these data suggest that the benefit of PTX in the prevention of AmpB-induced nephrotoxicity is, in part, due to vascular decongestion.
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Amphotericin B (AmpB) remains the most effective and widely used antibiotic for the treatment of systemic fungal disease in humans (11, 12) . Its use is frequently limited by the development of nephrotoxicity manifested by renal vascular resistance with diminished glomerular filtration rate and renal blood flow (7-10, 17, 20) . The inability to concentrate urine, as well as hyperkaluria and hypermagnesuria, are prominent clinical features of AmpB-associated nephrotoxicity. To date, the mechanism of this toxicity is not well understood, but it may be related to the interaction of the drug with membrane-bound cholesterol to form aqueous channels; thus, increased permeability to small solutes and decreased electrical resistance may occur at the cellular level (1, 4, 6) . The net effect is renal vasoconstriction and interstitial changes in electrolyte handling.
Pentoxifylline (PTX) is a unique hemorheologic agent useful in the treatment of intermittent claudication and other vascular diseases (16) . We have previously shown beneficial effects of PTX in the treatment of nephrotoxicity following cyclosporine (5) , glycerol, cisplatin, and mercuric chloride administration (21; unpublished data). Furthermore, complete restoration of glomerular filtration and renal blood flow has been associated with PTX use following ischemic events (13; D. R. Luke, K. L. Berens, and R. R. Verani, Renal Failure, in press). Morphologically, we have found significant reductions in vascular congestion in rat kidneys treated with PTX. The use of indomethacin does not interfere with the postischemic benefit of PTX, suggesting that the arachi-donic acid pathway does not play a major role in its mechanism of action.
The present study investigated the influence of PTX coadministration on both the acute and chronic nephropathies associated with AmpB. More importantly, the role of vascular congestion is implicated in the pathogenesis of AmpB-associated nephrotoxicity.
MATERIALS AND METHODS
Drugs. AmpB (Fungizone; E. R. Squibb & Sons, Princeton, N.J.) was reconstituted with sterile water; the reconstituted preparation remains stable for 7 days. PTX (Sigma Chemical Co., St. Louis, Mo.) was dissolved in sufficient saline for a resultant concentration of 45 mg/ml; since stability studies have not been performed, PTX solution was prepared fresh daily.
Animals. A total of 51 rats (male albino CD, 150 to 200 g; SASCO Breeders, Houston, Tex.) were housed in an animal facility with a 12-h light-dark cycle and controlled temperature and humidity. Powdered food (Purina rodent chow) and distilled water were unrestricted throughout the study. Rats were acclimated to individualized housing in a metabolism cage (Nalge/Sybron Corp., Rochester, N.Y.) for 2 days prior to study (K. Vadiei, K. L. Berens, and D. R. Luke, Lab. Anim. Sci., in press). Control animals were pair fed with drug-treated rats to avoid renal functional changes secondary to weight loss (Vadiei et Chronic studies. Animals (n = 24) were placed in individualized metabolism cages for baseline renal function assessment. Thereafter, each rat was randomized (stratified by baseline renal function) to receive single daily doses of 1 mg of AmpB per kg or an equivalent volume of sterile water (n = 12 each) via the penile vein for 10 days. The rats were further subdivided into equal groups receiving i.p. PTX (45 mg/kg) every 12 h or an equivalent volume of saline. Hence, four groups of six rats each were compared in the chronic studies. AmpB dosing preceded PTX administration by 1 h. On days 8 and 9, urine and blood samples were collected to reassess electrolyte handling and creatinine levels in serum. CLIN was calculated for each rat 24 h following the final AmpB dose as described previously.
Sample analysis. All blood samples were allowed to clot on ice and centrifuged at 13,000 x g for 2 min, and the serum was harvested and stored at -20°C until analyzed. Sodium and potassium concentrations in urine samples were measured by using ion-selective electrodes (NOVA 11+11 autoanalyzer). Serum samples were analyzed for creatinine concentrations by a modified Jaffe reaction (Beckman Creatinine Analyzer II The degree of vascular congestion on histologic examination was graded in the two drug-treated groups of rats in the acute study on a scale of mild to significant (1+ to 4+). Electrolyte excretion rates and CLIN were compared between groups by analysis of variance (PCANOVA; Human Systems Dynamics). Critical differences were assessed by Newman-Keuls post hoc tests. A difference was considered significant if the probability of chance explaining the results was reduced to less than 5% (P < 0.05). All data are expressed as mean + standard deviation.
RESULTS
Acute studies. Mean creatinine levels in serum of rats given AmpB, independent of PTX therapy, were significantly greater than those of controls (Table 1) . No differences in renal electrolyte handling were found between groups. PTX alone had no effect on CLIN compared with effects observed in control rats (Fig. 1) was associated with a 51% decline in CLIN (P < 0.01); coadministration of PTX and AmpB resulted in 88% of the mean control CLIN (1.07 ± 0.12 versus 1.22 ± 0.35 ml/min per g of kidney weight; not significant).
Microscopic examination of kidneys showed a prominent degree of vascular congestion in the majority of the rats given AmpB and saline as compared with rats treated with AmpB and PTX ( Fig. 2 and 3 ). All rats given AmpB and PTX had 1+ and 2 + vascular congestion in contrast to those given AmpB and saline, in which six of nine animals had 3 + to 4+ vascular congestion ( Table 1 ). The vascular congestion was more significant in the inner medulla and inner FIG. 3. Representative renal tissue of a rat 24 h after administration of a single dose of AmpB (1 mg/kg i.v.) and PTX (45 mg/kg i.p.). Vascular congestion is not observed (compare Fig. 2 ). Hematoxylin and eosin stain; magnification, x25. stripe of the outer medulla but was also observed in cortical vessels and glomerular capillaries. The animals treated with AmpB and PTX had a larger number of discoid erythrocytes. There was no evidence of tubular necrosis or tubular degeneration in any of the animals.
Chronic studies. Rats were pair fed throughout the study period; hence, weight loss was not significantly different between groups. Similarly, kidney weights were not significantly different among treatment groups. Significant increases in creatinine levels in serum were observed in AmpB control rats compared with levels in rats given AmpB and PTX, sterile water and PITX, and sterile water and saline (Table 1) . CLIN was markedly decreased in rats given AmpB and saline compared with CLINs in other groups (Fig. 1) . Renal sodium excretion was significantly greater in all three treatment groups than in saline controls. However, increased potassium excretion was found in rats receiving AmpB with or without PTX.
DISCUSSION
The renal toxicity profiles following single and multiple doses of AmpB have been well characterized in both experimental animals and humans (5, 7-9, 13, 15-18) . Consistent with drug-induced nephrotoxicities, decreased renal blood flow and significant increases in renal vascular resistance have been found in AmpB-treated animals. Coupled with findings of significant renal potassium and magnesium wasting, these data suggest both glomerular and tubular defects. Although an understanding of the mechanism of toxicity remains unclear, the renin angiotensin system and arachidonic pathway do not appear to play major roles (5, 16) . Others (6, 15) have suggested renal artery constriction with subsequent ischemia and the generation of superoxide anions; hence, theophylline has shown improvement in function by blocking ischemia-related adenosine effects (14) .
The present experiments suggest a further explanation: the role of vascular congestion resulting from ischemic blood flow. In the absence of oxygen, erythrocytes cannot maintain homeostasis. Swelling and loss of deformability of cells occur in the microvasculature, impairing further oxygen delivery. This vicious cycle continues until the appearance of tissue necrosis (15) . Multinucleated cells, such as neutrophils and polymorphonuclear cells, are attracted to the site of ischemia because of various chemotactic factors, including tumor necrosis factor, superoxide anions, and interleukin-1, released by circulating macrophages and monocytes. Indeed, leukostasis has been associated with AmpB use (2) . Furthermore, congestion at the site of ischemia may involve platelet activation and thrombogenesis. PTX effects on vascular congestion were confirmed by our histologic studies. Significant vascular congestion was found in six of nine rats given AmpB and water. In contrast, mild vascular congestion was found in rats administered AmpB and PTX. The increased deformability of the erythrocytes was also observed in animals given AmpB and PTX. This is a known effect of PTX on the fluidity properties of erythrocytes (3) .
PTX (19) ; hence, a reduction in the dose of PTX may result in a similar benefit in the AmpB toxicity model. To date, a dose-response curve has not been studied.
With PTX as a hemorheologic probe, the present data support the theory of vascular congestion as the primary factor for AmpB-associated toxicity. However, changes in renal electrolyte handling also occurred (in particular, increased potassium wasting). Although the absolute difference was modest in these experiments, hyperkaluria has been a significant problem in the clinical setting. The study was designed to treat drug-induced nephrotoxicity with PTX administered after the introduction of AmpB. It is possible that ischemic damage to the medullary thick ascending limb had occurred prior to the onset of activity of PTX. Pretreatment with PTX may offer increased protection from medullary damage.
In summary, the coadministration of PTX and AmpB resulted in preservation of glomerular function, most likely mediated by vascular decongestion. Since the use of AmpB is associated with high morbidity with dose-limiting toxicity to the kidney, the clinical implications of the present experiments are profound. However, further studies characterizing the effects of PTX on the antifungal activity of AmpB in the infected-animal model are warranted.
